Paraneoplastic movement disorders

作者: Robin Grant , Francesc Graus , None

DOI: 10.1002/MDS.22658

关键词: Stiff person syndromeOpsoclonusNeurological disorderNeuromyotoniaCancerPathologyMovement disordersMedicineOpsoclonus myoclonus syndromeCerebellar Degeneration

摘要: Paraneoplastic movement disorders are rare autoimmune nonmetastatic complications of cancer. Common paraneoplastic include cerebellar syndrome, opsoclonus myoclonus, basal ganglia disorders, stiff person and neuromyotonia. Syndromes usually present before cancer diagnosis commonly associated with one or more serum antibodies. Increasing numbers antibodies have been identified (Hu, Yo, Ri, CV2, amphiphysin, Ma, Ta, Tr, NMDA, mGluR1, PCA2, ANNA-3, VGCCA). Antibodies highly correlated the likelihood an underlying closely certain tumors. Clinical clues to aetiology speed onset, severity, progression, resistance treatment, widespread neurological signs than would expect from nonparaneoplastic aetiologies. Cancer should be sought in those classical presentations possible who If no tumor is found on initial investigation, interval screening advisable. The most common cancers small cell lung cancer, breast, gynaecological, testicular, lymphoma, thymoma. Early identification treatment sometimes leads improvement may improve prognosis. Prognosis dependent type its likely response treatment.

参考文章(79)
F. Bernal, S. Shams'ili, I. Rojas, R. Sanchez-Valle, A. Saiz, J. Dalmau, J. Honnorat, P. Sillevis Smitt, F. Graus, Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology. ,vol. 60, pp. 230- 234 ,(2003) , 10.1212/01.WNL.0000041495.87539.98
J Honnorat, J C Antoine, E Derrington, M Aguera, M F Belin, Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 61, pp. 270- 278 ,(1996) , 10.1136/JNNP.61.3.270
M Uchuya, F Graus, F Vega, R Rene, J Y Delattre, Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. Journal of Neurology, Neurosurgery & Psychiatry. ,vol. 60, pp. 388- 392 ,(1996) , 10.1136/JNNP.60.4.388
R. Linke, M. Schroeder, T. Helmberger, R. Voltz, Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. ,vol. 63, pp. 282- 286 ,(2004) , 10.1212/01.WNL.0000129983.06983.4E
F. Graus, B. Lang, P. Pozo-Rosich, A. Saiz, R. Casamitjana, A. Vincent, P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer Neurology. ,vol. 59, pp. 764- 766 ,(2002) , 10.1212/WNL.59.5.764
Keith A. Josephs, Takashi Ishizawa, Yoshio Tsuboi, Natalie Cookson, Dennis W. Dickson, A Clinicopathological Study of Vascular Progressive Supranuclear Palsy Archives of Neurology. ,vol. 59, pp. 1597- 1601 ,(2002) , 10.1001/ARCHNEUR.59.10.1597
Zhiya Yu, Thomas J. Kryzer, Guy E. Griesmann, Kwang-Kuk Kim, Eduardo E. Benarroch, Vanda A. Lennon, CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Annals of Neurology. ,vol. 49, pp. 146- 154 ,(2001) , 10.1002/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E
Florian Ertle, Wolfgang Behnisch, Naima Ali Al Mulla, Mohammed Bessisso, Dietz Rating, Gunhild Mechtersheimer, Barbara Hero, Andreas E. Kulozik, Treatment of neuroblastoma‐related opsoclonus–myoclonus–ataxia syndrome with high‐dose dexamethasone pulses Pediatric Blood & Cancer. ,vol. 50, pp. 683- 687 ,(2008) , 10.1002/PBC.21107
Michio Hirano, Recombinant enzyme replacement therapy for infantile-onset Pompe disease Current Neurology and Neuroscience Reports. ,vol. 8, pp. 45- 47 ,(2008) , 10.1007/S11910-008-0008-Z
Lawrence I. Golbe, Douglas C. Miller, Roger C. Duvoisin, Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism. Movement Disorders. ,vol. 4, pp. 147- 152 ,(1989) , 10.1002/MDS.870040206